RxDoctor Payments Data

Amy Hall

Family · Florence, ALNPI 1265815732

Payments from drug & device makers

$1,703in general payments, 2019–2025

Across 73 payments — averaging $23.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$527
  • AstraZeneca$218
  • Merck$169
  • AbbVie$160
  • Astellas Pharma US Inc$113
  • Lilly USA, LLC$111
  • plus $405 from 12 others

What the payments were for

  • Food & beverage$1,60394%
  • Education$1006%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,703 in reported general payments places this provider in the 70th percentile of 3,415 family providers in Alabama.

See all family providers in Alabama

Medicare billing

Part B allowed, 2024
$9,952
Medicare patients
48
Services billed
224

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide35$40,563
EliquisApixaban21$27,278
JardianceEmpagliflozin29$24,484
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$23,008
FarxigaDapagliflozin Propanediol16$17,541
Estradiol64$3,128
ProgesteroneProgesterone, Micronized58$1,903
Rosuvastatin Calcium28$1,587
Levothyroxine Sodium42$948
Fluoxetine Hcl19$935
Metoprolol Succinate37$914
Duloxetine Hcl14$617
Oxcarbazepine14$548
FenofibrateFenofibrate Nanocrystallized11$525
Isosorbide Dinitrate12$456

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$111$40,56335 claims
PfizerEliquis$25$27,27821 claims
Boehringer IngelheimJardiance$527$24,48429 claims
GSKTrelegy Ellipta$51$23,00817 claims
AstraZenecaFarxiga$218$17,54116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,415 family providers in Alabama.

Other family in Florence

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →